Medtronic plc (NYSE:MDT) delivered second-quarter fiscal 2026 results that topped analyst expectations on Tuesday, prompting shares to rise more than 4% intra-day. The company also lifted its full-year outlook, supported by strong performance from its cardiovascular division.
Adjusted EPS came in at $1.36, exceeding the $1.31 consensus. Revenue totaled $9 billion, above expectations of $8.87 billion and up 6.6% year over year, or 5.5% on an organic basis.
The Cardiovascular Portfolio led companywide growth, reporting a 10.8% revenue increase. Cardiac Ablation Solutions revenue jumped 71%, including 128% growth in the U.S., driven by robust demand for its pulsed field ablation products. Medtronic said this represented its strongest cardiovascular revenue performance in more than a decade, excluding pandemic distortions.
Based on its first-half momentum, Medtronic raised its fiscal 2026 organic revenue growth forecast to approximately 5.5%, up from 5.0%. The company also increased its full-year adjusted EPS guidance to $5.62–$5.66, compared with the prior range of $5.60–$5.66, aligning with the analyst consensus of $5.62.
